Navigation Links
Biovista Announces a Drug Repositioning Collaboration With Pfizer
Date:11/9/2010

mouseup", function (){ cf_jq(".cf_pushbutton_activate").live("mouseover", function (){ //Omniture Link Tracking Code /*var s=s_gi(s_account); s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.prop16='CrowdFactory_Share'; s.tl(this,'o', 'CrowdFactory_Share');*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106955943';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106955943';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ -- Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista's Clinical Outcome Search Space (COSS) technology.

Under the terms of the agreement, Biovista will collaborate with Pfizer's Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates. The terms of the agreement include an upfront payment and success-based milestones.

"We seek to benefit from the collaboration wit
'/>"/>

SOURCE Biovista
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
3. Novus Biologicals Awards Contract to Biovista Inc. to Drive its Web-Based Novus Explorer Service
4. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
5. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
6. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Anesiva Announces Second Quarter 2008 Financial Results and Update
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer ... agreement whereby the institutional investors will have the option ... Company up to $4.93M in near term funding, pending ... the restructured terms and subject to certain market conditions, ... result in a larger influx of capital to fund ...
(Date:6/2/2015)... 2, 2015 /CNW/ - Shell today celebrated the North American ... category with an exhibit the size of a city ... demonstrations for media and the public, and special appearances ... Premium Gasoline provides the best total engine protection by ... wear, gunk and corrosion. "With the launch ...
(Date:6/2/2015)... and TORONTO , June 2, ... TSX: APS), a clinical-stage company developing new therapeutics that ... the U.S. Food and Drug Administration (FDA) has granted ... treatment of acute myeloid leukemia (AML). APTO-253, a first-in-class ... product candidate in a Phase Ib clinical trial in ...
(Date:6/2/2015)... June 02, 2015 Global Stem Cells ... distributor for Bioquark, Inc.’s biologic products for the regeneration and ... latest in Global Stem Cells Group’s ambitious expansion plans in ... demand for access to regenerative medicine and stem cell therapies. ... development of biologics that have the ability to alter the ...
Breaking Biology Technology:TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3
... (Nasdaq: MSHL ), an oncology company focused on ... today that Charles Baltic, Managing Director and Co-Head of Healthcare ... of directors. The appointment of Mr. Baltic increases the number ... directors to five. "On behalf of the entire ...
... /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... biopharmaceutical companies in the People,s Republic of China, today ... annual list of Asia,s "200 Best Under a Billion" ... to the same list for the year 2009. ...
... Conn., Oct. 24, 2011 Modern Plastics, one of ... and medical-grade plastics, has become ISO 13485-2003 certified for ... Film and Resin. "This is an ... commitment to service and quality," said Bing J. Carbone, ...
Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 2China Biologic Named to Asia's "200 Best Under a Billion" by Forbes Asia 3
(Date:6/1/2015)... June 1, 2015 According to ... Sensing Market by Technology (Touch-based & Touchless), Application (Consumer ... & by Geography - Global Forecast to 2020", published ... is expected to reach $23.55 Billion by 2020, at ... Browse 83 market data T ables ...
(Date:6/1/2015)... 2015 According to a ... by Application (Government, Military & Defense, Healthcare, Banking ... Security), Technology (Face Recognition, Fingerprint Recognition, Iris Recognition, ... and Others), Function (Contact and Non-Contact) & Geography ... Europe , APAC, Row) - Global Forecast ...
(Date:5/29/2015)... , May 28, 2015 Research and ... of the "Facial Recognition Market by Solution, ... Global Forecast to 2020" report to their ... seen facial recognition technology become more efficient and ... gain traction and investment from the commercial sector. ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... like Alzheimer,s, Parkinson,s and Creutzfeldt-Jakob disease. But amyloid ... the development of new composite materials for the ... even make objects invisible. Researchers from Chalmers ... about amyloid in an article published in the ...
... in southern and eastern Canada may disappear from most of ... the toll on their habitat that scientists predict in a ... Climate Change . Scientists looked at reservoirs of genetic ... stable habitats. They found that caribou populations in the most ...
... Excellence for Coral Reef Studies (CoECRS) at James Cook ... of the world,s biggest environmental problems. Dr Christina ... CoECRS, holds a joint position with the Center for ... Dr Hicks says more powerful economic interests, such as ...
Cached Biology News:Alzheimer substance may be the nanomaterial of tomorrow 2Climate change threatens genetic diversity, future of world's caribou 2Linking social science and ecology to solve the world's environmental problems 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: